Valuation: PTC Therapeutics, Inc.

Market Cap 5.68B 4.93B 4.59B 4.22B 7.96B 542B 8.09B 54.14B 21.25B 270B 21.32B 20.85B 905B P/E 2026 *
39.2x
P/E 2027 * 24.4x
Enterprise Value 5.65B 4.91B 4.57B 4.19B 7.92B 539B 8.04B 53.86B 21.14B 268B 21.21B 20.74B 900B EV / Sales 2026 *
4.49x
EV / Sales 2027 * 2.6x
Free-Float
92.05%
Yield 2026 *
-
Yield 2027 * -
1 day-9.94%
1 week-11.47%
1 month-18.37%
3 months+4.39%
6 months-9.17%
Current year-10.47%
1 week 64.57
Extreme 64.5675
76.46
1 month 64.57
Extreme 64.5675
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
28/7/26 Other

Director

200,401 0.2416%
28/7/26 Free

Director

11,213 0.0135%
14/7/26 Sell

Chief Financial Officer

-3,494 0.0042%
Change 5-day change 1-year change 3-year change Capi.($)
-9.94%-11.47%+30.46%+69.18% 5.68B
-0.53%-3.95%+50.70%+152.78% 1,024B
+0.21%-2.68%+53.20%+50.87% 618B
-2.51%-3.25%+28.54%+67.99% 443B
+1.06%-0.81%+40.08%+33.81% 349B
+0.01%-1.42%+33.96%+42.26% 297B
-5.94%-7.84%+6.66%+8.97% 264B
-0.20%-6.46%-2.43%-43.10% 209B
-0.64%+2.43%+29.74%+67.16% 208B
-0.82%+0.70%+15.05%+72.05% 162B
Average -1.90%-2.36%+28.60%+52.20% 357.94B
Weighted average by Cap. -0.84%-2.18%+36.76%+73.15%

Financials

2026 *2027 *
Net sales 1.26B 1.09B 1.02B 934M 1.76B 120B 1.79B 11.99B 4.7B 59.73B 4.72B 4.62B 200B 1.36B 1.18B 1.1B 1.01B 1.91B 130B 1.94B 12.96B 5.09B 64.59B 5.1B 4.99B 217B
Net income 153M 133M 124M 114M 215M 14.63B 218M 1.46B 574M 7.28B 576M 563M 24.43B 215M 187M 174M 160M 302M 20.57B 307M 2.05B 806M 10.24B 809M 791M 34.33B
Net Debt -29.41M -25.56M -23.79M -21.84M -41.25M -2.81B -41.89M -280M -110M -1.4B -110M -108M -4.69B -2.15B -1.86B -1.74B -1.59B -3.01B -205B -3.06B -20.46B -8.03B -102B -8.06B -7.88B -342B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
31/07/26 USD 68.01 -9.94% 4,329,705
30/07/26 USD 75.52 +1.38% 1,374,880
29/07/26 USD 74.49 -1.19% 1,173,858
28/07/26 USD 75.39 -0.54% 1,487,692
27/07/26 USD 75.80 -1.33% 1,852,688
Trader
Investor
Global
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
68.01USD
Average target price
97.86USD
Spread / Average Target
+43.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock